Immuneering Corporation has reported encouraging results from the Phase 1 segment of its Phase 1/2a clinical trial for IMM-1-104.

Recce Pharmaceuticals Ltd, a company focused on developing synthetic anti-infectives to combat antibiotic resistance and emerging viral threats, has initiated a new phase in its clinical trials.

Preliminary results from a Phase 1b clinical trial of the drug NXP800, developed by Nuvectis Pharma, Inc., have shown promising signs in the treatment of platinum-resistant ARID1a-mutated ovarian cancer.

Nuvation Bio has initiated clinical trials for its first drug-drug conjugate (DDC), NUV-1511.

The company's research has discovered that the cytokines targeted by CAN10, namely IL-1, IL-33, and IL-36, are significantly elevated in the skin samples of systemic sclerosis patients.

Lantern Pharma's AI-driven drug candidate, LP-284, has entered a Phase 1 clinical trial, marking a significant step in the fight against cancer.

A recent clinical trial has shown promising results for the treatment of Fanconi Anemia (FA) using a new antibody therapy named briquilimab.

Recent updates from the BEXMAB clinical trial indicate a positive trend in the treatment of high-risk (HR) myelodysplastic syndrome (MDS) patients who have not responded to hypomethylating agents (HMA).

In Thousand Oaks, California, AliveGen USA Inc. has announced the successful conclusion of its Phase 1b multiple-ascending dose (MAD) clinical trial for the novel drug ALG-801.

Rezatapopt is a groundbreaking targeted therapy for advanced solid tumors with the TP53 Y220C mutation and KRAS wild-type.

Gunda Georg, co-creator of YCT-529, presented an update on the phase 1a clinical trial of the novel hormone-free male contraceptive pill at the American Chemical Society's Spring Meeting in New Orleans

DepYmed Inc. has announced that it has obtained approval from the U.S. Food and Drug Administration (FDA) to begin phase 1 clinical trials for DPM-1003.